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A B S T R A C T
Background: To address limitations in recruitment and enrollment of diverse, low-literacy patients into prostate
cancer clinical trials, we evaluated the feasibility, acceptability, and efficacy of an English and Spanish, Internet-
based, multilevel recruitment intervention.
Methods: Intervention components included (1) a low-literacy, bilingual, automated, Internet-based clinical trial
matching tool; (2) a bilingual nurse who assisted individuals with questions and enrollment; and (3) a targeted,
Internet-based advertising campaign. We evaluated (a) completion of matching tool, (b) expression of interest in
a clinical trial, (c) number of patients who matched to clinical trials at a single institution, (d) discussion of risks
and benefits of clinical trials (via follow-up interviews), and (e) effect of the advertising on completing the
matching tool. Feasibility, acceptability, and preliminary estimates of efficacy were measured through user
engagement with the matching tool and subsequent qualitative interviews with these same users.
Results: During the 28-week study period, 523 users provided demographic information, 263 were identified
with prostate cancer, 192 (73%) matched to at least one clinical trial, and 29 (15.1%) of those who matched
provided contact information. During the study period, 17 prostate cancer clinical trials were available for
matching. We completed follow-up interviews with 14 of the 29 men who provided contact information. Of the
14, 85.7% discussed the risks and benefits of clinical trials with their physician, and 35.7% enrolled in a clinical
trial. The Internet-based advertising campaign resulted in an increased number of matching tool completions.
Conclusions: Our study demonstrates that an Internet-based clinical trial matching tool that is advertised using a
targeted Internet-based campaign can provide an effective means to reach diverse, low-literacy patients. When
implemented at scale and over a longer duration, such interventions may help increase trial participation among
underrepresented populations.
1. Introduction
Advances in cancer diagnosis and treatment depend on the volun-
tary participation of diverse and representative patients in clinical trials
[1]. However, in the United States, less than 5% of all eligible adult
cancer patients participate in clinical trials [2]. Clinical trial enrollees
tend to be well-educated, middle class, and Caucasian, and as a result,
the problem of underrepresentation of minorities in clinical trials
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persists [3,4]. New strategies are required to improve recruitment of
underrepresented populations into cancer clinical trials. The Internet is
a logical resource for clinical trial advertisement and recruitment as
almost 86% of the U.S. population has regular access to the Internet [5].
Importantly, African Americans and Latinos have doubled their use of
the Internet in the last decade [6,7], making it a potentially important
tool in strategies designed to increase participation of these under-
represented groups.
Although several Internet-based clinical trial matching tools have
been developed, these tools are limited in scope and not designed to be
patient-friendly [8,9]. Users typically receive a list of trials with prin-
cipal investigator (PI) or site contact information, and eligibility criteria
often are described in complex medical jargon. Some tools offer limited
custom matching of individuals to trials, but these often require regis-
tration. Most tools are only available in English, which may limit
minority participation, and many are not tailored to individuals with
limited health literacy. A national database of clinical trials that was
developed to facilitate enrollment showed a positive impact on
matching and recruiting patients into prevention trials; however, this
database did not facilitate final enrollment [10], suggesting a need for
further engagement (e.g., personal interaction) and patient navigation
once a possible match is identified [10–12]. Additionally, a study of
users of a breast cancer clinical trials matching tool showed that those
who did not find their match results “relevant” cited that most of the
trials matched to them were located far away [13]. Finally, most ex-
isting clinical trial matching tools lack an individualized service that
could answer patients' or family members' questions. Some sites may
offer a phone service, though this is meant to guide callers through the
matching process without offering additional information about the
trial or alternatives to participating in the trial. These limitations result
in inadequate recruitment and enrollment of diverse, low-literacy pa-
tients into cancer clinical trials.
The utility of the Internet to disseminate health information to
minority Americans was recognized early on [14]; however, little is
understood regarding the online research-seeking behavior of under-
represented populations within the United States. Frameworks gener-
ated from the field of internet technology adoption could be extra-
polated to better understand the development of utilizing matching
tools to increase participation in clinical trials [15]. The development of
matching tools was broadly based on the technology acceptance model
which proposes that the perceived usefulness and the perceived ease-of-
use of the new technology are essential elements for its adoption [16].
These two elements were essential in the development of this internet-
based matching tool intervention.
To address these issues of inadequate recruitment efforts of diverse
patients in clinical trials, we evaluated the feasibility (tested in a lim-
ited way) [14], acceptability (by the intended audience) [14], and in-
itial measures of efficacy of an English and Spanish, multilevel re-
cruitment intervention. This pilot study was conducted at the
University of California San Francisco (UCSF) Helen Diller Family
Comprehensive Cancer Center (HDFCCC), using prostate cancer clinical
trials. We hypothesized that pairing a matching tool with personalized
navigator services to assist patients through trial selection and enroll-
ment was likely to enhance participation [12,17], as navigator services
embedded in cancer care have had positive effects on clinical trial re-
cruitment [15,18]. Thus, in addition to a low-literacy, bilingual (Eng-
lish and Spanish) Internet-based clinical trial matching tool, we in-
cluded a bilingual nurse navigator to facilitate enrollment. To attract
users, particularly minorities, to this the matching tool, we initiated a
broad community-based Internet advertising campaign.
2. Materials and methods
2.1. Study setting
The study was conducted between October 1, 2014 and April 15,
2015. The Spanish version of the matching tool was initiated on March
1, 2015 and was maintained until the end of the study. The Internet-
based matching tool was available to anyone with Internet access, using
standard search engines, or by the user selecting an advertisement on
prostate cancer-related UCSF websites. The active Google AdWords
advertising campaign (described below) was geographically targeted to
the San Francisco Bay Area, with a particular focus on areas and
neighborhoods with higher proportions of Latino and African American
residents based on census data. The study was approved by the UCSF
Institutional Review Board.
2.2. Description of intervention
The intervention consisted of three components: 1) a low-literacy,
bilingual (English and Spanish), automated, Internet-based clinical trial
matching tool; 2) a bilingual nurse who assisted interested individuals
with questions and facilitated enrollment into clinical trials; and 3) a
broad community-based Internet advertising campaign.
2.2.1. Internet-based clinical trial matching tool
The Internet-based clinical trial matching tool used in this study,
which was hosted on a UCSF-supported website, was designed to be
accessible to patients with limited health literacy and to present the
fewest barriers to participation. The matching tool, which was em-
bedded in the HDFCCC homepage, did not require registration, was
offered in English and Spanish, asked the minimum number of ques-
tions needed to match participants to trials, and was programmed to
offer only those trials tailored to the patient's personal prostate cancer
characteristics. The tool's website and algorithm were built using the
Qualtrics Research Suite, a HIPAA-compliant cloud-based survey pro-
gram. Individuals arrived to the matching tool by clicking on either the
link embedded in the HDFCCC website, searching for clinical trials
using any internet search engine, clicking on our study's advertisement
(when the Google AdWords advertising campaigns were active), or
from other sources (e.g., word of mouth, etc.). At any given point
during the study period, there were 17 interventional clinical trials for
patients with various stages of prostate cancer open for accrual at UCSF.
Patients using the Internet-based matching tool, or family members
or friends using the tool on the patient's behalf, were asked to complete
a brief assessment to determine the patient's eligibility for the available
clinical trials. To further maximize inclusion, in addition to applying a
registration-free platform, we utilized only a small number of the most
relevant screening questions. Considering our goal of serving low health
literacy participants, we anticipated that not all respondents would
have complete information about the patient's disease characteristics or
medical history. Thus, we were concerned that using an “inclusion-
only” algorithm (that is, individuals must fit all criteria that a specific
clinical trial requires) would inadvertently screen out otherwise ap-
propriate participants from clinical trials. Instead, we used a “non-ex-
clusion” algorithm, whereby participants were deemed as “possibly
matched” to a trial unless they specifically reported clinical information
that would make them ineligible. To maximize the chances of including
all patients who were potentially eligible for a trial, we asked about
broad health criteria rather than more specific disease characteristics.
The matching algorithm used all available clinical data from the
participant to match them to active trials at UCSF and displayed sum-
maries of each trial to which an individual had been matched. All
summaries were written at a sixth-grade reading level in both Spanish
and English and presented in a clear, simple format. To minimize
confusion, each summary was displayed on a separate page. Both
general information and trial-specific details about eligibility, benefits,
risks, and procedures were included. After each summary, participants
were asked whether they were interested in the trial. Users who in-
dicated interest in any matched trial were given an opportunity to
submit their name, phone number, and other contact information. If
contact information was submitted, an automated email containing the
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relevant user information (contact information, clinical data, possible
matches, interest indicated) was sent to the nurse navigator. Users for
whom no match was found were informed of their ineligibility for any
current trials and presented with links to other UCSF and National
Cancer Institute resources. Patients or their family members who re-
quested information were given a telephone number or an email where
they could send a request.
2.2.2. Bilingual nurse navigator
An oncology nurse, bilingual in Spanish and English, was assigned
to respond to phone and email requests from users of the matching tool.
The nurse responded to participants based on their answers to the
screening items, including information on the participant's diagnosis
and health characteristics, knowledge of clinical trials, and potential
barriers to participation. The nurse further assessed and confirmed
eligibility for specific trials, provided additional verbal and/or written
information about trials, and facilitated recruitment visits with appro-
priate clinical trial investigators. For this study, the nurse's role was
solely to provide information to facilitate the participants' personal
decision-making. The nurse navigator was not a member of any study
team associated with specific clinical trials.
2.2.3. Internet-based advertising campaign
To increase community participation in prostate cancer clinical
trials, and especially the participation of minorities, an Internet-based
advertising campaign targeting the greater San Francisco Bay Area was
developed. The advertising campaign was launched using Google
AdWords, a fee-based service. AdWords bypasses Google's PageRank
search result algorithm by displaying a specific advertisement (“ad”)
link among search results to the right of the page when an individual
enters predetermined keywords into a Google search query (e.g.,
prostate clinical trial). By clicking on a study ad, the user was directed
to the matching tool site. AdWords can geographically target ads, with
some precision, based on the Internet Protocol (IP) address of the user's
device, which in turn is based on specific zip codes or a custom radius
around arbitrary geographical coordinates. For mobile devices, Global
Positioning Service (GPS) and cell towers are used to determine the
current geographical location of the device, triggering ads relevant to
that location. For this study, ads were targeted to the San Francisco Bay
Area and specifically to those areas with a larger proportion of African-
American, Latino, and Asian-American residents. The ads were run for
three separate periods: October 28, 2014 to November 3, 2014 (one-
week test), January 21, 2015 to February 12, 2015 (three weeks and 2
days), and March 12, 2015 to April 6, 2015 (three weeks and 5 days).
Within all three periods, ads were run in English; Spanish ads ran only
during the last period. The ads automatically took the user to the
matching tool in the same language as the ad. The ads contained s brief
description of the clinical trial matching tool. Using various keywords
and groups of ads, AdWords allowed us to closely monitor the perfor-
mance of individual ads and keywords (i.e., which ads or keywords
were more likely to result in a site visit). Ineffective ads and keywords
were eliminated in favor of better performing ones [19].
2.3. Measures
2.3.1. Demographic indicators
We collected demographic information about each person who used
the matching tool: whether the user currently had prostate cancer or
was a friend or family member of someone who was diagnosed with
prostate cancer; age (categorized as ≤39, 40–75 years, 76–85,> 85);
self-reported race/ethnicity (non-Latino white, Latino, African
American, Asian or Pacific Islander, or American Indian and other
groups); education level (high school/GED or less, some college or as-
sociate degree, bachelor's degree, or graduate education, and current or
past utilization of UCSF medical center as a cancer care provider.
2.3.2. Health literacy
Health literacy was assessed with using three validated questions to
determine the following: (1) the frequency with which the patient re-
quired a family member, friend, hospital worker, or caregiver to help
read hospital materials; (2) the patient's concerns regarding a lack of
understanding of his own medical condition due to difficulty under-
standing written information; and (3) the patient's level of discomfort
with filling out medical forms alone [20,21]. Response categories for
each item ranged from always (1) to never (5). We dichotomized re-
sponses to “always/often/sometimes” versus “rarely/never.”
2.3.3. Health indicators
The following prostate cancer-related indicators were included in
the analysis: time since diagnosis (≤6 months, > 6 months, or not
sure); PSA level at diagnosis (< 10 ng/ml, ≥ 10 ng/ml, or not sure);
current PSA level status (increasing versus decreasing, or not sure);
Gleason score (6, 7, ≥ 8, or not sure); whether or not the cancer had
spread (metastasized to lung, liver, bone, and/or brain; cancer has not
metastasized; not sure); prior prostate cancer treatments if any (pros-
tate surgery, internal or external radiation therapy, hormone therapy
injections, hormone therapy pills, chemotherapy, or cryosurgery).
2.3.4. Outcome indicators
The feasibility of this study was assessed with several outcomes: 1)
completion of the matching tool, 2) expression of interest in a clinical
trial by providing contact information, and 3) matching to a clinical
trial. The effect of the Internet-based advertising campaign on the use of
the matching tool was also evaluated. Potential impact of the inter-
vention was assessed among those participants who provided contact
information via follow-up qualitative interviews. We assessed discus-
sion of risks and benefits of clinical trial participation with a physician
and subsequent clinical trial participation. These patients were called
once a week until contacted or until three attempts had been made
without response. For patients who received medical care at UCSF, we
assessed whether they participated in a clinical trial. We assessed the
acceptability of the study by examining participants' feedback. We in-
quired about participants' thoughts about the matching program, in-
cluding whether (a) the site was easy to use, (b) the matching results
were useful, and (c) the information was easy to understand. Response
options included “yes,” “somewhat,” and “no.”
2.4. Statistical analysis
Descriptive statistics were used to characterize users who were
identified as having a prostate cancer diagnosis. Among participants
with prostate cancer, bivariate analyses compared demographic and
clinical characteristics of those who matched to at least one clinical trial
compared to those who did not. Among those who matched to a clinical
trial, we compared those who provided contact information versus
those who did not. In addition, we compared the demographic char-
acteristics of those who completed the tool during the Google AdWords
campaign versus those who completed the tool outside the ad campaign
period. Chi-square tests were carried out to assess any significant dif-
ferences between categorical variables, and t-tests were used to assess
differences in continuous variables (two-tailed significance level
p < 0.05).
3. Results
3.1. Characteristics of participants
During the 28-week study period, 523 of those who responded
completed at least some demographic information. Of these, 263
(50.2%) identified themselves as having prostate cancer (Table 1).
Approximately two-thirds (64.6%) of participants with prostate cancer
answered the questions for themselves, whereas over a third (35.4%)
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were doing so on behalf of someone with the disease. Most (84.4%)
were between the ages of 40 and 75 years old. More than three-quarters
(75.7%) of these participants identified as non-Latino white, 10.6% as
Asian American, 6.8% as Latino, and 4.2% as African American.
The number of Latino respondents with prostate cancer who used
the matching tool increased considerably once the Spanish-language
version of the tool was launched. During a 21 ½-week period when the
matching tool was available only in English, 5 (3.3%) respondents
identified as Latino compared to the 13 (5.3%) respondents in the 6
½-week period after making the tool available in Spanish.
Less than a third (30.1%) of participants reported having less than a
bachelor's degree. A quarter (24.0%) of participants reported needing
help reading materials given to them by a doctor or hospital, 32.0%
reported they had at least some difficulty understanding written ma-
terials regarding their medical condition, and 16.9% reported not being
comfortable filling out medical forms by themselves.
As for clinical characteristics, more than a third (36.1%) of the
participants with prostate cancer received the diagnosis within the past
six months, 36.1% reported a PSA score of ≥10 ng/mL, and 56.7%
noted their PSA score was climbing (Table 2). Over a third (35.4%) of
the participants reported a Gleason Score≥ 8, and 31.2% indicated
their cancer had not metastasized. Among those who reported prior
treatment, 19.2% reported undergoing prostate surgery, 25.1% radia-
tion therapy, 33.9% hormone therapy injections, 23.0% hormone
therapy pills, 13.5% chemotherapy, and 1.5% cryosurgery.
3.2. Matching to trials
There were 17 prostate cancer clinical trials available over the
course of the study for participants to be matched to during the study
period (between 8 and 12 trials were open at any given point during the
study), and 73% of men with prostate cancer matched to at least one of
these trials. Among those who matched to a clinical trial (n= 192),
nearly three-quarters (73%) matched to at least one trial and the
median number of matched trials was 3, with a mean of 3.5 (SD=2.2;
range 1–10). Among the 29 men with prostate cancer who provided
contact information (15.1%), the median number of trials was 3, with a
mean of 3.4 (SD=2.1; range 1–7).
3.2.1. Participants who matched to a clinical trial
Participants who matched to a clinical trial were significantly less
likely to report for themselves, (30.2% versus 49.3% p < 0.01) and
more likely to be white (78.1 versus 69.0 p < 0.05) compared to those
who did not match to a trial (Table 1). In addition, those who matched
were less likely to need help reading materials (18.5% versus 42.4%
p < 0.0001), to have difficulty understanding written materials
(27.0% versus 42.4% p < 0.05), and to feel uncomfortable filling out
medical forms (13.8% versus 25.8%, p < 0.05).
There were also several significant clinical differences between the
men who matched to at least one clinical trial and those who did not
match (Table 2). Men who matched were significantly more likely to be
diagnosed within six months of using the matching tool (42.7% versus
Table 1
Characteristics of participants who identified with prostate cancer.
Identified with Prostate
Cancer
Matched V. Not Matched to a Trial Contact Information among Matched Participants
No Match Matched P Value Did Not Provide
Information
Provided
Information
P Value
N=263 N=71 27% N=192 73% N=163 84.9% N=29 15.1%
% % % % %
Individual Completing Matching Tool Survey
Self 64.6 49.3 30.2 < 0.01 68.7 75.9 ns
Someone else 35.4 50.7 69.8 31.3 24.1
If someone else, family member or
friend
72.0 100 82.8 0.01 80.4 100 ns
Age
≤39 years 0.8 1.4 0.5 ns 0.6 0 ns
40–75 years 84.4 84.5 84.4 83.4 89.6
76–85 years 11.8 14.1 10.9 11.7 6.9
>85 years 3.0 0.0 4.2 4.3 3.5
Ethnicity
Non-Latino white 75.7 69.0 78.1 0.05 77.9 79.2 ns
Latino 6.8 14.1 4.2 4.3 3.5
African American 4.2 2.8 4.7 3.7 10.3
Asian or Pacific Islander 10.6 9.9 10.9 12.3 3.5
American Indian and other groups 2.7 4.2 2.1 1.8 3.5
Education
High school/GED 10.3 13.0 9.5 ns 10.0 6.9 ns
Some college or AA 19.8 27.5 17.5 15.6 27.6
Bachelor's degree 26.6 20.3 29.6 28.7 34.5
Graduate education 41.4 39.1 43.4 45.6 31.0
Missing 1.9 – – – –
Health Literacy (always, often, sometimes)
Needs help reading materials 24.0 42.4 18.5 < 0.0001 18.1 20.7 ns
Difficulty understanding written
materials
32.0 42.4 27.0 < 0.05 26.9 27.6 ns
Not comfortable filling out medical
forms
16.9 25.8 13.8 < 0.05 12.5 20.7 ns
UCSF Patient
No 67.6 58.2 73.2 ns 71.4 82.8 ns
No, but I have been one 16.0 20.9 12.1 13.0 6.9
Yes 14.1 20.9 14.7 15.5 10.3
Missing 2.3 – – – –
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21.3%, p < 0.0001), to have PSA levels lower than 10 ng/mL (63.0%
versus 36.1%, p < 0.0001), and to report no metastasis (40.1% versus
7.0%, p < 0.0001). They also were less likely to report hormone
therapy injections (26.5% versus 53.6%, p < 0.0001), hormone
therapy pills (13.4% versus 48.6%, p < 0.0001), and receipt of che-
motherapy (3.7% versus 40.6%, p < 0.0001).
3.2.2. Participants who provided contact information
Among men who matched to at least one trial, men who provided
contact information were not significantly different from those who did
not provide information with one exception: Men who left contact in-
formation were less likely to report higher Gleason scores (≥8) than
those who matched to a clinical trial (51.8 versus 45.7, p < 0.01).
3.3. Reach of Google AdWords
Fig. 1 shows the effect of the Internet ad campaigns on matching
tool usage. The ad campaign was active in three separate phases for 7 of
the 28 total weeks of the pilot study. Overall, the campaign increased
the number of individuals with prostate cancer who completed the
matching tool and who provided contact information. Over half of the
participants reaching the study came via clicking on a Google AdWords
ad (60.1% versus 39.9%), despite the ads running for less than 25% of
the study time period. The average number of matching tool comple-
tions per week was 1.1 during weeks when the ads were not running
compared to 9.0 per week when the ads were active. The number of
people interested in clinical trial participation, measured by those who
left contact information, increased as well. During weeks when ads
were running, on average, 1.17 participants per week provided contact
information compared to 0.07 participants per week when ads were not
running.
The study spent approximately $500 per week when ads were
running. The most used keywords were prostate cancer clinical trials,
prostate, clinical trials, prostate cancer treatment, and prostate tumor.
Comparison of demographic characteristics between those who re-
sponded during Google AdWords period and those who responded
outside the ad periods indicates that there were no significant differ-
ences between the two groups with one exception: Those who answered
the ads were more likely to have experienced prostate cancer them-
selves (Table 3).
3.4. Contact, follow-up interviews, and participation in clinical trials
Twenty-nine participants provided their contact information, three
of whom died sometime between their use of the tool and our attempts
to contact them for a follow-up interview. We completed 14 follow-up
interviews (48.3% response rate). Based on the interview data, it was
determined that 12 of 14 (85.7%) interview participants discussed the
risks and benefits of enrolling in a clinical trial either with their primary
care physician or a UCSF oncologist. Five men enrolled in a clinical
trial, three of whom did so at UCSF. This represents a 35.7% partici-
pation rate in all trials regardless of location (5/14) and a 21.4% par-
ticipation rate in UCSF clinical trials (3/14) among those who com-
pleted follow-up interviews. Reasons reported for not enrolling at UCSF
Table 2
Clinical characteristics of participants who identified with prostate cancer.
Identified with Prostate Cancer Matched V. Not Matched to a Trial Contact Information among Matched Participants
N=263 N=192
No Match Matched P Value Did Not Provide Information Provided Information P Value
N=263 N=71 27% N=192 73% N=163 84.9% N=29 15.1%
% % % % %
Time since Cancer Diagnosis
6 months ago or less 36.1 21.3 42.7 < 0.0001 41.7 48.3 ns
More than 6 months ago 58.9 73.8 57.3 58.3 51.7
Not sure 1.1 4.9 0.0 – –
Missing 3.8
PSA Level at Diagnosis
<10 ng/mL 54.4 36.1 63.0 < 0.0001 66.3 44.8 ns
≥10 ng/mL 36.1 50.8 33.3 30.1 51.7
Not sure 5.7 13.1 3.6 3.6 3.5
Missing 3.8
PSA Level Status
Increasing 56.6 64.7 62.7 ns 63.1 60.7 ns
Decreasing 12.2 21.6 11.4 11.5 10.7
Unchanged 12.2 7.8 15.1 14.6 17.9
Not sure 8.7 5.9 10.8 10.8 10.7
Missing 10.3 – – – –
Gleason Score
6 14.7 3.6 19.4 < 0.0001 22.2 3.5 <0.01
7 22.1 10.9 27.2 23.5 48.3
≥8 35.4 54.5 33.0 34.6 24.1
Not sure 21.3 30.9 20.4 19.7 24.1
Missing 6.5
Cancer Spread
No metastases 31.2 7.0 40.1 < 0.0001 42.9 24.1 ns
Metastasis 68.8 93.0 59.9 57.1 75.9
Prior Prostate Cancer Treatment
Prostate surgery 19.2 17.1 19.9 ns 19.1 24.1 ns
Radiation therapy 25.1 31.0 22.9 ns 22.1 27.6 ns
Hormone therapy injections 33.9 53.6 26.5 < 0.0001 24.4 37.9 ns
Hormone therapy pills 23.0 48.6 13.4 < 0.0001 12.7 17.2 ns
Chemotherapy 13.5 40.6 3.7 < 0.0001 3.7 3.4 ns
Cryosurgery 1.5 0.0 2.1 ns 1.9 3.4 ns
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included limitations imposed by third party insurance, travel distance,
and lack of information and/or contact from UCSF personnel.
Enrollment in a trial somewhere other than UCSF by men who did not
make an appointment at UCSF or who were not reached by telephone or
e-mail for a follow-up interview could not be determined.
3.5. Feedback on the matching program
Forty-nine participants provided feedback on the Internet-based
clinical trial matching tool. Of those, almost all (98%) reported the site
was easy to use. Three-quarters (74.5%) found the matching results
useful, while 19.1% found them somewhat useful. Almost all the re-
spondents (97.9%) reported that the information provided was easy to
understand.
4. Discussion
This pilot study provided evidence that an automated, Internet-
based clinical trial matching tool with targeted Internet-based adver-
tising is feasible, acceptable, and effective in reaching men with pros-
tate cancer. In addition, this study demonstrated that geographic tar-
geting and the use of Spanish-language matching tool and
advertisements increased the proportion of Latino participants. These
findings are supported by similar studies examining Internet matching
tools [22]. However, our study population was 25% non-white com-
pared to 10% in similar matching studies and was able to reach a higher
proportion of minority populations [22]. Spratt and colleagues reported
that African American men comprise about 3.3% of phase III rando-
mized clinical trials in prostate cancer [23]. Our study found that 5.1%
of participants who used the matching tool when the Google AdWords
campaign was live identified as African American. The targeted geo-
graphical areas and diversity of the Northern California population, as
well as the effort to target the Latino population, may account for these
discrepancies.
This approach was relatively easy to implement, leveraging avail-
able off-the-shelf technology. A widely used Qualtrics survey platform
was employed to construct a simple website, which included a
matching tool algorithm that required minimal upkeep. The feasibility
and applicability of this model is reflected, in part, by the resource
efficiency of the program. Although initial efforts are required to design
the questionnaire, program the Internet-based tool, and prepare the
trial summaries provided to participants, maintenance further along is
required only as trials open and close.
The matching tool was designed to reduce participant burden while
broadening their options. This approach matched participants to trials
fitting their specific clinical situation. This is different from other al-
gorithms that only roughly match a participant's condition to a clinical
trial. For example, traditional matching to the extent of disease (e.g.,
metastatic prostate cancer) critically misses hormonal status (sensitive
or resistant), which is an equally important determinant of trial elig-
ibility. Conversely, this tool avoided overemphasis on granular clinical
details to eliminate a potential source of participant frustration and to
minimize risk of inaccurate responses, limiting the relevance of parti-
cipant-trial matches. This approach generated a broad yet relevant list
of trials for each participant, allowing for a greater choice and more
information regarding potential trials. Additionally, participants who
used the matching tool found it easy to navigate and did not identify
complexity of the language nor the amount or length of questions as
barriers to participation.
This approach is among the first to implement Spanish-language
Fig. 1. Survey completion, survey participants with prostate cancer, and survey participants who left information.
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support along with IP-address targeted advertising in an effort to in-
crease clinical trial access among underrepresented minorities. When
Spanish-language version was run, the proportion of Latino respondents
more than tripled, from 9% to 30%. When implemented at scale and
over a longer duration, such interventions may help to better balance
demographic representation among trial participants. While prostate
cancer clinical trials continue to underrepresent racial/ethnic mino-
rities [23], these findings suggest that underrepresented minorities are
actively seeking online health information. Therefore, this study serves
as an important rationale for future investigators to develop novel In-
ternet-based interventions to deliver health information to a diverse
population of men with prostate cancer. The approach applied in this
study can be translated into other social media platforms with adver-
tisements, such as Facebook and Twitter. Future interventions can
continue to target advertisements to geographical areas where mino-
rities or Spanish speakers reside in an effort to reduce the overall cost of
recruitment.
There are a number of limitations to this study; most reflect the fact
that this was a pilot feasibility study. First, only a small proportion of
the Internet-based tool users enrolled in a trial during the study period.
The decision to participate in a cancer clinical trial is complex, and
assessing eligibility is just a starting point. There are a number of pa-
tient and physician contextual attributes that inform the decision to
proceed with trial enrollment. The decision to participate in trials is an
ongoing process, one in which potential participants establish care
through a cancer center active in clinical research and with ongoing
evaluation and discussion thereafter. While this pilot study obtained
only preliminary estimates of efficacy on enrollment, a large number of
person-to-person contacts and in-office visits occurred due to the
matching tool. These users otherwise may never have made contact
with a cancer research center; therefore, increased enrollment down-
stream may not be captured fully. Due to the complexity of clinical trial
accrual, this feasibility study was not designed to ultimately measure
the impact of this intervention on increasing accruals to clinical trials.
Second, although there appeared to be a significant impact of
Spanish-language matching tool and advertising, a formal comparison
of advertising with and without Spanish-language advertisements was
not undertaken. The increase in the proportion of Latino respondents
was based on a relatively small sample size, during a relatively short
time period of advertising in Spanish.
Finally, when the pilot was launched, the time requirement of the
bilingual patient navigator was not known, and in retrospect, it is clear
that insufficient effort was budgeted to this project. Although many
participants accessed the Internet-based clinical trial matching tool,
human-to-human contact remained the key component in the genera-
tion of dialogue, including meaningful in-office visits to discuss clinical
trial enrollment. Our post-participation interviews revealed that lack of
person-to-person outreach on behalf of the cancer program was the
main reason for failure to establish a visit and/or trial enrollment.
Conversely, all patients who scheduled visits at our center, including
those ultimately enrolling in trials, reported prompt contact by phone
or email on behalf of study personnel as their main conduit towards
visitation and enrollment. Consequently, the results reported may be
skewed by this rate-limiting step.
5. Conclusions
In summary, this pilot program has shown that a personalized,
questionnaire-based online approach (i.e., the matching tool), can im-
prove access and potentially facilitate enrollment among individuals
who otherwise may not participate in clinical trials. Both the ease of use
and the broad reach of the Internet-based tool, and therefore the po-
tential recruitment strength of this program, are reflected in the number
of total users who completed the matching tool. Ultimately, this pro-
gram served as an additional avenue through which patients, especially
those who may not have considered a clinical trial as a viable option,
were able to access trial participation. Today, online health information
resources for a diverse population of men with prostate cancer are
limited. While caution for the digital divide may have exacerbated
disparities in health information resources, this study highlights the
acute need for and investment in more robust Internet health in-
formation infrastructure. Future studies will need to deliver more
comprehensive online resources for a diverse population of men with
prostate cancer.
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